Free Republic
Browse · Search
Bloggers & Personal
Topics · Post Article

To: 2aProtectsTheRest
said, "said in a different thread, "the vaccines(from the US) are safe and effective"
--2aProtectsTheRest 4/25/2021
standing by it saying "There is no data to suggest otherwise"

Yes there is
two vaccines on early phase of the tests I looked in to
Oxford–AstraZeneca COVID-19 vaccine standard dose there was 23 severe reactions on page 16
https://www.thelancet.com/cms/10.1016/S0140-6736(20)32466-1/attachment/f9742c1b-2e28-4d3f-aaff-9d6f0302f673/mmc1.pdf

Pfizer vaccine they played a Shell game in testing. The Pfizer vaccine that went to millions of people is BNT162b2. The standard dose they used in testing was BNT162b1. They did have lots of adverse reactions with BNT162b2. Even with most of them getting low and medium doses.
https://clinicaltrials.gov/ct2/show/record/NCT04368728

They've tested other mRNA vaccines to date none could be approved without corruption of the medical industry.
196 posted on 04/26/2021 1:01:16 PM PDT by Steve Van Doorn (*in my best Eric Cartman voice* 'I love you, guys')
[ Post Reply | Private Reply | To 190 | View Replies ]


To: Steve Van Doorn

AstraZeneca’s vaccine is not available in the United States. The number of severe reactions to it has been so small that it’s still in use in many places around the world, but it’s not in use here. In fact, they haven’t even filed the paperwork asking for approval.

Pfizer tested both BNT162b1 and BNT162b2 in pre-clinical trials and in Phase 1/2 clinical trials. After those trials, BNT162b2 was selected for Phase 3 clinical trials because it elicited more effective immune response. Here’s their own words:

“BNT162b2 demonstrated concurrent induction of high magnitude CD4+ and CD8+ T cell responses. BNT162b2 elicited T cell responses against the receptor binding domain (RBD) and against the remainder of the spike glycoprotein that is not contained in the BNT162b1 vaccine candidate. The companies believe that immune recognition of more spike T cell epitopes may have the potential to generate more consistent responses across diverse populations and in older adults.”

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-0


198 posted on 04/26/2021 1:07:30 PM PDT by 2aProtectsTheRest (The media is banging the fear drum enough. Don't help them do it.)
[ Post Reply | Private Reply | To 196 | View Replies ]

Free Republic
Browse · Search
Bloggers & Personal
Topics · Post Article


FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson